Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 4/20 | 0.33 |
| ▸ | CDK2 | P24941 | 4/20 | 0.33 |
| ▸ | KDR | P35968 | 3/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17841539 | 0.81 | GAA (0.37) | GAATBK1 | |
| SCHEMBL29421585 | 0.81 | GAA (0.37) | GAATBK1 | |
| SCHEMBL31634163 | 0.79 | GAA (0.36) | GAACDK1CDK2KDRCCNB1 | |
| SCHEMBL22234790 | 0.79 | CDK1 (0.45) | GAACDK1CDK2KDRCCNB1 | |
| SCHEMBL29598152 | 0.79 | CDK1 (0.45) | GAACDK1CDK2KDRCCNB1 | |
| SCHEMBL29951713 | 0.74 | HSP90AA1 (0.32) | CDK1CDK2CCNB1LRRK2CCNA2 | |
| SCHEMBL6825991 | 0.73 | CCNA2 (0.38) | CDK1CDK2CCNB1LRRK2CCNA2 | |
| SCHEMBL736170 | 0.73 | KDM4E (0.34) | GAALRRK2 | |
| SCHEMBL22234711 | 0.73 | GAA (0.45) | GAACDK1CDK2KDRCCNB1 | |
| SCHEMBL6823092 | 0.72 | GAA (0.31) | GAACDK1CDK2KDRCCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635279-A2 | CHEMICAL COMPOUNDS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2013-09-11 | — | — | EP | disclosed |
| US-20130225524-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| WO-2012061557-A2 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225524-A1 | Chemical Compounds | LDHA, NQO2, LDHB | GAA 387/4885CDK1 493/4885CDK2 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.